Clinical trial · Observational
Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer
The Role of Mitochondrial Bioenergetics in Resilience in Older Adults With Gynecologic Cancer Receiving Cancer Reductive Treatment
NCT07046936CI-TRIAL-00119862MITO-RESrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to see if patients with endometrial and ovarian cancer are willing to complete physical and cognitive assessments before treatment and again after treatment has ended.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gynecologycal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood draw | Other | — | UNRESOLVED |
| muscle sample | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Advanced gynecological cancers
- description
- Participants 50 years and older with suspected or newly diagnosed advanced gynecological cancer (ovarian/primary peritoneal/fallopian tube or endometrial carcinoma of any histological subtype) who are planned to undergo SOC treatment.
- interventionNames
- Diagnostic Test: muscle sample
- Other: blood draw
Primary outcomes (4)
- measure
- Screening rate
- timeFrame
- Screening
- description
- Proportion of approached patients who signed consent out of the total number of patients who were approached
- measure
- Enrollment rate
- timeFrame
- Screening and pretreatment
- description
- Proportion of consented participants who initiated at least one pretreatment assessment or had pretreatment blood drawn out of the total number of consented participants
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Ability to understand and willingness to sign an IRB-approved informed consent * Age ≥50 years at the time of enrollment * Newly diagnosed or suspected FIGO Stage II-IV ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype OR FIGO Stage II-IV endometrial carcinoma of any histological subtype * Planned, standard of care treatment consisting of neoadjuvant chemotherapy, tumor reduction surgery, and adjuvant chemotherapy OR tumor reduction surgery with adjuvant chemotherapy * Ability to read and understand the English language Exclusion Criteria: * Previously treated for ovarian or endometrial cancer * History of brain metastases, whole brain irradiation, poorly controlled psychiatric disorders defined by hospitalization within the last 3 months for psychiatric diagnoses, traumatic brain injury, cerebrovascular event, or dementia * Currently taking anti-amyloid agents, cholinesterase inhibitors, or glutamate regulator * Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study
References
Publications (0)
Data not yet available
No reference posted for this study.